{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-032604","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2023-07-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.163491+00:00","generated_at":"2026-06-13T09:25:14.780908+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Ultragenyx appoints Howard Horn as CFO and EVP, Corporate Strategy effective Oct 16, 2023","bullets":["Howard Horn appointed CFO and EVP, Corporate Strategy effective October 16, 2023.","Base salary of $590,000/year, target bonus 50%, sign-on bonus of $60,000.","Equity award with target value of $6 million: 50% options, 50% RSUs vesting over 4 years.","Previously CFO at Vir Biotechnology (2017-2023) and held finance roles at Biogen.","Will lead finance, accounting, corporate strategy, and investor relations at Ultragenyx."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-032604","json":"https://secwatch.observer/filing/0000950170-23-032604.json","markdown":"https://secwatch.observer/filing/0000950170-23-032604.md","text":"https://secwatch.observer/filing/0000950170-23-032604.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023032604/0000950170-23-032604-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023032604/rare-20230712.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T09:25:14.780908+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a658e31d90","claim":"Howard Horn was appointed as Chief Financial Officer and Executive Vice President, Corporate Strategy at Ultragenyx Pharmaceutical Inc..","evidence_excerpt":"On July 12, 2023, Ultragenyx Pharmaceutical Inc. (the “Company”) announced that Howard Horn has been appointed as the Company’s Chief Financial Officer and Executive Vice President, Corporate Strategy, effective as of October 16, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023032604/0000950170-23-032604-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer and Executive Vice President, Corporate Strategy"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}